Board Change • May 20
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Pauline Gately is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. 공시 • Mar 31
Elixinol Wellness Limited, Annual General Meeting, May 27, 2026 Elixinol Wellness Limited, Annual General Meeting, May 27, 2026. 공시 • Sep 08
Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,800,000
Price\Range: AUD 0.0135
Discount Per Security: AUD 0.00081
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 138,385,185
Price\Range: AUD 0.0135
Discount Per Security: AUD 0.00081
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing 공시 • Jun 04
Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million. Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 0.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,571,429
Price\Range: AUD 0.0175
Discount Per Security: AUD 0.00105
Transaction Features: Subsequent Direct Listing 공시 • May 21
Elixinol Wellness Limited has filed a Follow-on Equity Offering. Elixinol Wellness Limited has filed a Follow-on Equity Offering.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: Subsequent Direct Listing 공시 • Mar 19
Elixinol Wellness Limited, Annual General Meeting, May 20, 2025 Elixinol Wellness Limited, Annual General Meeting, May 20, 2025. 공시 • Oct 28
Elixinol Wellness Limited Announces Resignation of Tai Phan as Joint Company Secretary, Effective 25 October 2024 Elixinol Wellness Limited announced that Mr. Tai Phan has resigned as Joint Company Secretary, effective 25 October 2024. Ms. Melanie Leydin continues in the role of Company Secretary and, for the purposes of ASX Listing Rule 12.6, remains the primary person responsible for communication between the Company and the ASX. 공시 • Apr 03
Elixinol Wellness Limited, Annual General Meeting, May 30, 2024 Elixinol Wellness Limited, Annual General Meeting, May 30, 2024. 공시 • Mar 28
Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF). Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. Under the terms of agreement, Elixinol Wellness will pay AUD 2 million as upfront payment and AUD 1 million as earnout consideration. Elixinol Wellness Limited will raise AUD 3.16 million through Rights Issue Offer which will be used in part to finance the acquisition. The deal is expected to be completed by the end of March, 2024. Completion of the Ananda Food acquisition is conditional on raising sufficient funds under the Rights Issue Offer and the satisfaction of a number of customary conditions. As of March 20, 2024, the transaction is expected to close on March 28, 2024.
Elixinol Wellness Limited (ASX:EXL) completed the acquisition of Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) on March 28, 2024. Ron Dufficy will now be stepping down from the role of Group Chief Executive Officer and Natalie Butler will join the EXL Board. Reported Earnings • Mar 01
Full year 2023 earnings released: AU$0.016 loss per share (vs AU$0.033 loss in FY 2022) Full year 2023 results: AU$0.016 loss per share (improved from AU$0.033 loss in FY 2022). Revenue: AU$9.05m (up 28% from FY 2022). Net loss: AU$7.51m (loss narrowed 29% from FY 2022). 공시 • Feb 14
Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million. Elixinol Wellness Limited (ASX:EXL) entered into Conditional agreement to acquire Ananda Food Pty Ltd from Ecofibre Limited (ASX:EOF) for AUD 3 million on February 12, 2024. The deal is expected to be completed by the end of March, 2024. Board Change • Oct 10
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Non-Executive Director Dave Fenlon is the most experienced director on the board, commencing their role in 2022. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Sep 04
First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.023 loss in 1H 2022) First half 2023 results: AU$0.009 loss per share (improved from AU$0.023 loss in 1H 2022). Revenue: AU$3.46m (up 7.4% from 1H 2022). Net loss: AU$3.40m (loss narrowed 52% from 1H 2022). Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. New Risk • Sep 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 98% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.4m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Market cap is less than US$10m (€3.37m market cap, or US$3.63m). Minor Risks Currently unprofitable and not forecast to become profitable next year (AU$4.7m net loss next year). Revenue is less than US$5m (AU$7.6m revenue, or US$4.9m). New Risk • Aug 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$8.2m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (€3.05m market cap, or US$3.33m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.6m net loss in 2 years). Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (AU$7.1m revenue, or US$4.6m). 공시 • May 24
Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Elixinol Wellness Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 55,555,555
Price\Range: AUD 0.018
Discount Per Security: AUD 0.00108
Security Features: Attached Options 공시 • May 23
Elixinol Wellness Limited Announces Company Secretary Changes Elixinol Wellness Limited advised that Ms. Teresa Cleary has resigned as Company Secretary of Elixinol Wellness, effective immediately. The Board would like to take this opportunity to thank Ms Cleary for her outstanding contribution to the Company over the last three and half years and genuinely wishes her well with her future endeavours. Ms Josephine Lorenz, the Company's Group Chief Financial Officer, has been appointed as Joint Company Secretary, effective immediately. Ms Sarah Prince, Joint Company Secretary and Ms Lorenz are the persons responsible for communications with the ASX in relation to ASX Listing Rule matters. Reported Earnings • Mar 03
Full year 2022 earnings released: AU$0.033 loss per share (vs AU$0.054 loss in FY 2021) Full year 2022 results: AU$0.033 loss per share (improved from AU$0.054 loss in FY 2021). Revenue: AU$7.58m (down 19% from FY 2021). Net loss: AU$10.6m (loss narrowed 38% from FY 2021). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
First half 2022 earnings released: AU$0.023 loss per share (vs AU$0.035 loss in 1H 2021) First half 2022 results: AU$0.023 loss per share (up from AU$0.035 loss in 1H 2021). Revenue: AU$3.34m (down 30% from 1H 2021). Net loss: AU$7.13m (loss narrowed 34% from 1H 2021). Reported Earnings • Feb 26
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: AU$0.054 loss per share (up from AU$0.58 loss in FY 2020). Revenue: AU$11.8m (down 21% from FY 2020). Net loss: AU$17.0m (loss narrowed 84% from FY 2020). Revenue exceeded analyst estimates by 36%. Reported Earnings • Aug 22
First half 2021 earnings released: AU$0.035 loss per share (vs AU$0.60 loss in 1H 2020) The company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: AU$4.79m (down 39% from 1H 2020). Net loss: AU$10.8m (loss narrowed 88% from 1H 2020). Reported Earnings • Feb 28
Full year 2020 earnings released: AU$0.58 loss per share (vs AU$0.50 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: AU$14.3m (down 47% from FY 2019). Net loss: AU$104.5m (loss widened 59% from FY 2019).